Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

FDI inflows to Romania reached EUR 5.7 billion, reflecting a 14% decrease from EUR 6.6 billion in 2023, according to ...

A prominent marketer in the consumer healthcare industry, Ed Round has joined Cornerstone Design and Marketing in the new ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

The vitamin and mineral brand Vitrum made a remarkable return to the Georgian market at the end of 2023. It quickly regained ...

In a saturated pharmaceutical landscape, where the number of vitamin D supplements continues to rise each year, Vitaferol stands out ...

All SDRs and shares allocated have now been delivered to the counterparties, with a transfer of 7.5 million treasury shares ...